115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
文拉法辛对抑郁症患者炎症水平的影响
Authors Zhang H, Huang N, Ma X, Liu Y
Received 29 May 2025
Accepted for publication 10 December 2025
Published 14 January 2026 Volume 2026:22 543189
DOI https://doi.org/10.2147/NDT.S543189
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Taro Kishi
Huan Zhang,1 Na Huang,2 Xinxin Ma,1 Yanan Liu3
1Department of Psychiatry, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Central Laboratory, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 3Department of Psychiatry, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China
Correspondence: Huan Zhang, Department of Psychiatry, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157, Xiwu Road, Xi’an, Shaanxi, 710004, People’s Republic of China, Tel +86-029-87679349, Fax +86-029-87679349, Email zhanghuan_huanz@163.com
Background: Venlafaxine is widely applied to treat depression. Herein, we further explore the effect of venlafaxine on inflammatory level in patients with depression.
Methods: Retrospectively, the medical data of patients (from January 2020 to February 2023, following up for 1 year) with depression (n=134) and without depression (health group, n=63) were collected. According to different treatment methods, patients with depression were categorized into the venlafaxine group (n=71) and the fluoxetine group (n=63). After treatment 8 weeks and 1 year, the baseline characteristics, therapeutic effect, inflammatory level and adverse events were analyzed.
Results: After treatment 8 weeks and 1 year, there were significant improvements about depression and inflammatory level in venlafaxine group and fluoxetine group (P< 0.05), showing as the obvious decreases of Hamilton depression scale-17 (HAMD-17) score, C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-4, IL-6 and neutrophil/lymphocyte ratio (NLR). Furthermore, the improvements of depression and inflammatory level were obvious in venlafaxine group than those of in fluoxetine group (P< 0.05). There was no significant difference about adverse events between venlafaxine group and fluoxetine group.
Conclusion: In this study, venlafaxine use was associated with improvement in depressive symptoms and correlated with reduced levels of inflammatory markers in patients with depression.
Keywords: depression, venlafaxine, inflammatory level, therapeutic effect, Hamilton depression scale-17
1Department of Psychiatry, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 2Central Laboratory, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China; 3Department of Psychiatry, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, People’s Republic of China
Correspondence: Huan Zhang, Department of Psychiatry, The Second Affiliated Hospital of Xi’an Jiaotong University, No. 157, Xiwu Road, Xi’an, Shaanxi, 710004, People’s Republic of China, Tel +86-029-87679349, Fax +86-029-87679349, Email zhanghuan_huanz@163.com
Background: Venlafaxine is widely applied to treat depression. Herein, we further explore the effect of venlafaxine on inflammatory level in patients with depression.
Methods: Retrospectively, the medical data of patients (from January 2020 to February 2023, following up for 1 year) with depression (n=134) and without depression (health group, n=63) were collected. According to different treatment methods, patients with depression were categorized into the venlafaxine group (n=71) and the fluoxetine group (n=63). After treatment 8 weeks and 1 year, the baseline characteristics, therapeutic effect, inflammatory level and adverse events were analyzed.
Results: After treatment 8 weeks and 1 year, there were significant improvements about depression and inflammatory level in venlafaxine group and fluoxetine group (P< 0.05), showing as the obvious decreases of Hamilton depression scale-17 (HAMD-17) score, C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-4, IL-6 and neutrophil/lymphocyte ratio (NLR). Furthermore, the improvements of depression and inflammatory level were obvious in venlafaxine group than those of in fluoxetine group (P< 0.05). There was no significant difference about adverse events between venlafaxine group and fluoxetine group.
Conclusion: In this study, venlafaxine use was associated with improvement in depressive symptoms and correlated with reduced levels of inflammatory markers in patients with depression.
Keywords: depression, venlafaxine, inflammatory level, therapeutic effect, Hamilton depression scale-17